Wall Street economists are anxiously awaiting Wednesday's FOMC meeting.Marketsread more
Normally, when the Fed starts loosening policy it does so amid clear-cut signs of economic weakness.Economyread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
CNBC's Jim Cramer connects the dots by reasoning that if the president were to act, he would pick a successor to Powell that would do his bidding.Economyread more
Judy Shelton said in an interview that, if appointed to the Fed, she would want to lower interest rates all the way down to 0%.The Fedread more
Shoppers are "very nuanced in their expectations," Ron Johnson, the former CEO of J.C. Penney and the former senior vice president of Apple's retail division, said at CNBC's...Evolveread more
The winner will live in a centrally located apartment, receive a "salary" and explore the city to find what makes people there so happy.Liferead more
Beyond Meat has blown up. The plant-based meat company is now larger than 80 S&P 500 companies, including Macy's, Xerox and Mylan.Trading Nationread more
We've been given plenty of reasons to quit Facebook, including a new report that alleges disgusting working conditions at a company, Cognizant, it uses to employ contractors....Technologyread more
This just might be Fed Chair Jerome Powell's toughest meeting yet, because whatever the outcome, odds are high that it will disappoint a large group.Market Insiderread more
Jefferies' research team named its favorite picks of biotech stocks that are expected to have good news in the coming months.
"Biotech continues its Road to Repair and is near 1-year highs," wrote Jefferies analyst Michael Yee in Thursday's note to clients. Scrutiny over the sector's pricing practices has subsided, general interest in the sector has picked up, and there is recent M&A activity, he said.
"Our thesis continues to be the sector has been beaten down for 2 years and [is] pretty cheap vs health care and broader market."
Jefferies said that the industry's ever-improving backdrop coupled with a shift in investor focus to fundamentals bodes well for the sector.
Here are four companies that made Jefferies' recommended list and the firm's price targets for each.